Major pharmaceutical companies select Insightful’s S-PLUS software and life sciences solutions over the past 12 months
SEATTLE - May 23, 2007 -
Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive analytics and reporting solutions, today announced building momentum with large life sciences customers, including both new and expanding engagements over the past 12 months to integrate cutting edge analytics and graphics into all phases of the drug development life cycle.
Insightful counts a majority of the world’s leading pharmaceutical companies as customers, including Pfizer, Inc., AstraZeneca International, Johnson & Johnson, and Hoffman-La Roche, Inc. During the past 12 months, each of these four companies and many of the other leading pharmaceutical companies started new life sciences solutions projects with Insightful, expanded existing projects, or purchased more software licenses from Insightful.
Pfizer, Inc. has signed an agreement to deploy S-PLUS predictive analytics software within the company. Insightful's agreement with Pfizer is based on software license and maintenance fees.
Life Sciences Solutions Provide the Knowledge to Act™
Insightful provides life sciences organizations with the knowledge they need to drive faster, better decisions with specialized analytics, graphics and reporting formats. Insightful offers software and service solutions in clinical graphics, PK/PD reporting, clinical data review, innovative trial design, and safety data mining. These solutions are designed to act in concert with existing data management and workflow systems within validated environments to speed the analysis and reporting processes, to increase the likelihood of discerning safety and efficacy signals earlier in the development lifecycle thus decreasing our customers’ product development costs and time to market.
“The agreement with Pfizer, which was signed in December, was one of several with large life sciences companies over the past 12 months, which we believe reflects pharmaceutical companies’ demand for faster, better and more cost effective ways to analyze their data and report their results in all phases of the drug development lifecycle,” said Jeff Coombs, president and CEO of Insightful. “The analytic rigor and graphic superiority of our S-PLUS platform for pre-clinical, clinical, and regulatory submissions have been recognized by our customers as setting a standard of excellence in the industry.”
Statistical analysis software
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment